Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extra measles shot at 4 months may slash child deaths

NCT ID NCT01668745

Prevention Sponsor: Bandim Health Project Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving babies an extra measles vaccine at 4 months old, in addition to the standard shot at 9 months, could reduce deaths. Over 4,500 children in Burkina Faso and Guinea-Bissau took part. The goal was to see if early vaccination provides extra protection beyond just preventing measles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

4,559 people

The number who actually took part.

Started

May 2013

Finished

Jun 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 6 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Children who * received the third dose of pentavalent vaccine at least 28 days before enrolment * are between 4 and 6 months old * belong to households of the existing HDSS Exclusion Criteria: Children * with serious malformation * who are severely sick (needing hospitalisation) * with high fever (\>38.5 C axillary temperature) * who are severely malnourished (mid-upper-arm-circumference (MUAC) \< 110 mm and/or bilateral peripheral oedema) * who have received neonatal vitamin A supplementation * whose parents/guardians state that they intend to permanently move out of the study area before the child reaches 9 months of age

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles vaccine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Measles vaccine

Contacts and locations

Locations

  • Centre de Recherche en Sante de Nouna

    Nouna, Burkina Faso

More trials for these conditions

Other studies related to the condition(s) this trial covers.